Model Delfia Xpress -Random Access Platform for Prenatal Screening
Dedicated random access prenatal screening platform from the leader in the field. DELFIA® Xpress has been developed to streamline workflows in laboratories and clinics providing prenatal screening services. Already in use in more than 50 countries, DELFIA Xpress offers a range of benefits critical for operational efficiency., The speed and flexibility of random access, The simplicity and ease of use of a new generation instrument with up-to-date software design, The security associated with barcoded reagents and samples to ensure positive identification, The reassurance from using reliable, proven DELFIA chemistry, The flexibility to support connections to 3rd party software such as Viewpoint and Astraia, as well as PerkinElmer’s clinically validated LifeCycle™ screening management software with new MFH risk calculation engine with statistical analysis tool.
Leaders in prenatal screening for over 20 years
PerkinElmer provides state-of-the-art solutions to benefit maternal and fetal health. Our solutions comprise instruments, reagents and screening management software, all based on our broad-ranging expertise and understanding of today’s needs.
7.9 million screens per year
We are the global leader in products for detecting fetal anomalies during pregnancy, and our platforms are used in more than 50 countries to perform some 7.9 million prenatal risk assessments per year. The newest of PerkinElmer’s prenatal platforms, DELFIA Xpress has become the platform of choice in many parts of the world.
A full range of 1st and 2nd trimester kits are available for DELFIA Xpress and hence it supports the strategies being implemented by today’s screening programs. The instrument is equally at home in clinics and in laboratories. Our research investment in maternal health has led to the development of several new or soon-to-be-available products to allow a wider choice of strategies in aneuploidy screening, and to help programs that are considering pre-eclampsia screening.
Total fl exibility to handle the workload
DELFIA Xpress provides all the benefi ts of a random access system. You can load multiple samples in one go or you can load individual samples as soon as they arrive for testing. The instrument takes 30 minutes to process a patient sample, and generates results at a rate of 40 per hour. The STAT capability provides total fl exibility in the handling of patient samples, with the ability to introduce samples as priority if desired. From an operator point of view, all that is required to interrupt a run is to press the start/pause button, and the instrument’s ”traffi c lights” indicate when the STAT sample can be loaded.
Positive identifi cation of all components
All kit contents are bar-coded. When a reagent item is loaded into the DELFIA Xpress instrument, the bar code is automatically read. Specimen tubes, if they are bar-coded, are also read within the instrument. A hand-held bar code reader is used to input all kit lot information, and can also be used for manual feeding of specimen barcodes.
Saves space in the laboratory or clinic
Many instruments compete for space in today’s modern laboratories. DELFIA Xpress is a new generation bench-top instrument that maximizes performance from a footprint of only 85 x 56 cm. Operation of the instrument is handled through the PC based workstation software, designed to facilitate easy navigation.
The reliability of DELFIA® chemistry
The reliable clinical performance of DELFIA Xpress assays owes much to the well-established, superior DELFIA chemistry employed by the system. DELFIA reagents are widely used in research, drug discovery, neonatal and prenatal screening, and diagnostics.
Optimized controls available
Ideal for use with DELFIA Xpress, Maternal Health Control – Early is a set of controls with PAPP-A and free hCGb targeted at clinically important levels for 1st trimester screening. Available exclusively through PerkinElmer, the controls are produced by Sero AS, a specialist in quality control material.
Ideal for OSCAR
An ideal solution for delivering OSCAR (one stop clinic for assessment of risk) services, DELFIA Xpress has been chosen by several pioneering programs. Among these are the Early Prenatal Risk Assessment Program of Calgary, Ontario, Canada, and the program of the Harris Birthright Research Centre for Fetal Medicine based at King’s College, London, UK.
New assays for early pre-eclampsia screening
Pre-eclampsia is the most common of the serious complications of pregnancy, and early identification of high risk pregnancies is an important step towards improved management of such cases. However, screening on the basis of maternal history alone provides inadequate sensitivity and specificity. A more effective method of screening for pre-eclampsia is provided by combining maternal history with other markers. One of today’s preferred serum markers is placental growth factor (PlGF). PlGF also has value in improving the performance of Down syndrome screening. Optimized for first trimester measurement, the DELFIA Xpress PlGF assay provides a result that is valid in both pre-eclampsia and Down syndrome risk calculations.